Scott H Kaufmann MD PhD
Hematologic Oncology
Consultant in Hematology Mayo Clinic Rochester, MN
Join to view full profile
200 1st St SwRochester, MN 55905
Phone+1 507-284-2511
Dr. Kaufmann is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1985 - 1987- Johns Hopkins UniversityResidency, Internal Medicine, 1982 - 1985
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1981 - 1982
- Johns Hopkins University School of MedicineClass of 1981
Certifications & Licensure
MN State Medical License 1995 - 2027
MD State Medical License 1985 - 1994
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia
- Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia
- Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
Publications & Presentations
PubMed
- 1 citationsMitochondrial metabolic vulnerabilities in high-grade serous ovarian cancer.Anjali Prasad, Scott H Kaufmann, Arun Kanakkanthara
Biochimica Et Biophysica Acta. Reviews on Cancer. 2026-07-01 - Differences in overall survival for invasive epithelial ovarian cancer by race and ethnicity: results from the Ovarian Cancer Association Consortium.Nicola S Meagher, Kami K White, Lynne R Wilkens, Hoda Anton-Culver, Elisa V Bandera
British Journal of Cancer. 2026-06-30 - N-Glycosylation of AXL Receptor Tyrosine Kinase Regulates Its Stability, Phosphorylation, and Oncogenic Function.Li Wang, Lingrui Li, Jidong Wang, Kishore Garapati, Feifei Li
Molecular & Cellular Proteomics. 2026-06-01
Journal Articles
- Methylation of All BRCA1 Copies Predicts Response to the PARP Inhibitor Rucaparib in Ovarian CarcinomaScott H Kaufmann, Elizabeth M Swisher, Nature
Abstracts/Posters
- A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)Scott H. Kaufmann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic S...Scott H. Kaufmann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
The Deubiquitinase USP36 Regulates DNA Replication Stress and Confers Therapeutic Resistance Through PrimPol StabilizationNovember 25th, 2020
Grant Support
- Therapy of PARP inhibitor-associated myeloid neoplasms in ovarian cancer patientsMAYO CLINIC ROCHESTER2024–2029
- MSTP at Mayo Clinic RochesterMAYO CLINIC ROCHESTER2023–2028
- MSTP at Mayo Clinic RochesterMAYO CLINIC ROCHESTER2023–2028
- Cause and therapeutic impact of DNA-protein crosslink repair defect in myeloid leukemiasMAYO CLINIC ROCHESTER2021–2026
- Cause and therapeutic impact of DNA-protein crosslink repair defect in myeloid leukemiasMAYO CLINIC ROCHESTER2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
